利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

55 条记录 (耗时 0.023 秒)

    Novel immunotherapy
    4.
    发明申请
    Novel immunotherapy 审中-公开
    新型免疫治疗

    公开(公告)号：US20050220760A1

    公开(公告)日：2005-10-06

    申请号：US10817423

    申请日：2004-04-02

    申请人： Thomas Scott ,  Heather Borick ,  Ginger Swire-Clark ,  William Marcotte ,  Ashby Bodine

    发明人： Thomas Scott ,  Heather Borick ,  Ginger Swire-Clark ,  William Marcotte ,  Ashby Bodine

    IPC分类号： A61K38/17 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K39/00 ,  A61K39/395

    CPC分类号： C07K14/78 ,  A61K38/00 ,  A61K38/1777 ,  C07K2319/00

    摘要： Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes α6β1 integrin receptors and/or α6β4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 α3 chain that has been shown to bind α6β1 integrin receptors and α6β4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 α3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.

    摘要翻译： 公开了使用针对致病病原体的疾病的试剂在病原体表面上包含α6β1整联蛋白受体和/或α6β4整联蛋白受体的治疗剂和治疗方法。 在一个实施方案中，该疾病可以是乳腺癌。 所公开的治疗剂包括包含已显示结合α6β1整联蛋白受体和α6β4整联蛋白受体的层粘连蛋白-5α3链的至少一部分G结构域的多肽。 在一个实施方案中，治疗剂可以是其中层粘连蛋白-5α3链多肽化学结合到可用于破坏或中和病原体的另一种材料的融合或嵌合物质。

    Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
    5.
    发明申请
    Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof 有权
    用于鉴定lap（潜伏相关肽）和整合蛋白alpha.v.3b之间的相互作用的调节剂的方法及其医疗用途

    公开(公告)号：US20030176315A1

    公开(公告)日：2003-09-18

    申请号：US10276947

    申请日：2003-05-05

    发明人： Simon Barry ,  Carmel Horgan ,  Steven Ludbrook ,  David Miller

    IPC分类号： A61K031/00 ,  G01N033/53

    CPC分类号： A61K38/1777 ,  A61K38/1841 ,  G01N2333/70557 ,  G01N2500/00

    摘要： A method for the identification of a modulator of the interaction between latency associated peptide (LAP) of transforming growth factor null1 (TGF-null1) and the integrin avb3, which method comprises: (a) providing, as a first component, LAP-null1 or a functional variant thereof; (b) providing, as a second component, integrin avb3 or a functional variant thereof; (c) contacting the two components with a test product under conditions that, in the absence of the test product, would permit the two components to interact; and (d) determining whether the test product is capable of modulating the interaction between the first and second components, thereby to determine whether the test product is a modulator of the interaction between LAP-null1 and integrin avb3.

    摘要翻译： 用于鉴定转化生长因子β1（TGF-β1）的潜伏相关肽（LAP）与整联蛋白avb3之间相互作用的调节剂的方法，该方法包括：（a）提供作为第一组分的LAP-β1 或其功能变体; （b）提供整合素avb3或其功能变体作为第二成分; （c）在没有试验产品的情况下允许两种组分相互作用的条件下使两种组分与测试产物接触; 和（d）确定测试产品是否能够调节第一和第二组分之间的相互作用，从而确定测试产品是否是LAP-β1和整合素avb3之间相互作用的调节剂。